Oppenheimer & Co. Inc. Takes Position in Nuvectis Pharma, Inc. (NASDAQ:NVCT)

Oppenheimer & Co. Inc. purchased a new position in shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 25,000 shares of the company’s stock, valued at approximately $135,000. Oppenheimer & Co. Inc. owned approximately 0.13% of Nuvectis Pharma as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of NVCT. Nations Financial Group Inc. IA ADV acquired a new position in Nuvectis Pharma during the 3rd quarter worth approximately $63,000. GSA Capital Partners LLP lifted its position in Nuvectis Pharma by 3.7% during the 3rd quarter. GSA Capital Partners LLP now owns 50,129 shares of the company’s stock worth $315,000 after acquiring an additional 1,790 shares in the last quarter. Forbes J M & Co. LLP lifted its position in Nuvectis Pharma by 21.9% during the 4th quarter. Forbes J M & Co. LLP now owns 59,000 shares of the company’s stock worth $319,000 after acquiring an additional 10,599 shares in the last quarter. Geode Capital Management LLC lifted its position in Nuvectis Pharma by 49.8% during the 3rd quarter. Geode Capital Management LLC now owns 79,716 shares of the company’s stock worth $501,000 after acquiring an additional 26,489 shares in the last quarter. Finally, Baldwin Wealth Partners LLC MA lifted its position in Nuvectis Pharma by 104.4% during the 4th quarter. Baldwin Wealth Partners LLC MA now owns 355,961 shares of the company’s stock worth $1,926,000 after acquiring an additional 181,831 shares in the last quarter. 96.77% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Nuvectis Pharma

In other Nuvectis Pharma news, major shareholder Marlio Charles Mosseri bought 17,000 shares of the business’s stock in a transaction on Friday, December 13th. The shares were bought at an average cost of $4.70 per share, with a total value of $79,900.00. Following the transaction, the insider now directly owns 2,612,000 shares in the company, valued at approximately $12,276,400. This trade represents a 0.66 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have acquired a total of 261,500 shares of company stock valued at $1,300,825 in the last three months. Corporate insiders own 35.78% of the company’s stock.

Nuvectis Pharma Stock Up 12.7 %

Shares of NVCT opened at $6.93 on Monday. The business’s 50 day moving average is $6.46 and its two-hundred day moving average is $6.40. Nuvectis Pharma, Inc. has a 52-week low of $4.44 and a 52-week high of $12.10. The firm has a market cap of $162.11 million, a price-to-earnings ratio of -5.97 and a beta of 0.23.

Nuvectis Pharma (NASDAQ:NVCT) last announced its earnings results on Tuesday, March 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.08). On average, equities analysts expect that Nuvectis Pharma, Inc. will post -1.01 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reduced their price target on Nuvectis Pharma from $21.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, February 25th.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.